Search company, investor...
IXICO company logo


Founded Year




Total Raised


Market Cap



IXICO is a medical imaging company that provides software solutions and services to deliver imaging biomarkers in clinical trials, research studies and health care diagnostics.

Headquarters Location

Griffin Court, 15 Lone Lane 4th Floor

London, England, EC1A 9PN,

United Kingdom


IXICO's Product Videos

Compete with IXICO?

Ensure that your company and products are accurately represented on our platform.

IXICO's Products & Differentiators


    Individually tailored consultation to define best imaging endpoints and analysis methodologies to deliver requisite insights

Expert Collections containing IXICO

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

IXICO is included in 2 Expert Collections, including Clinical Trials Tech.


Clinical Trials Tech

364 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.


Biopharma Tech

326 items

IXICO Patents

IXICO has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Image processing, Digital photography, Open formats, Image compression, Medical imaging


Application Date


Grant Date



Related Topics

Image processing, Digital photography, Open formats, Image compression, Medical imaging



Latest IXICO News

IN BRIEF: Ixico shares down as annual revenue expected to drop

Oct 25, 2022

09/21 10/25/2022 | 07:44am EDT Message : *Required fields Ixico PLC - London-based neuroscience data analytics company - Expects revenue in year ended September 30 to be GBP8.6 million, down from GBP9.2 million the year before. Says year-on-year revenue fall reflects the "impact of the early cessation of client trials during the year". Order book amounts to GBP16.0 million at year-end, down from GBP18.8 million in prior year. "This reflects the signing of GBP12.6 million of new contracts during the year, offset by the delivery of GBP8.6 million revenue and GBP6.8 million contract value reductions due to the early client trial cessations and minor foreign exchange differences", Ixico notes. Says revenue guidance for financial 2023 remains unchanged. In May, Ixico reported a fall in pretax profit to GBP201,000 in the half-year ended March 31, from GBP635,000 a year ago due to the impact of cancelled client trials. Revenue dropped to GBP3.9 million from GBP4.9 million. Chief Executive Officer Giulio Cerroni says: "The company has delivered a strong close to the year as new contracts signed in the early months of 2022 initiate. The investments and adoption of our technology platform in new clinical trials enable us to continue to build our position as a trusted partner of choice to the global biopharmaceutical industry." Current stock price: 30.06 pence, down 4.6% on Tuesday afternoon in London 12-month change: down 58%

May 27, 2022
Final Results

IXICO Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo


IXICO Frequently Asked Questions (FAQ)

  • When was IXICO founded?

    IXICO was founded in 2004.

  • Where is IXICO's headquarters?

    IXICO's headquarters is located at Griffin Court, 15 Lone Lane, London.

  • What is IXICO's latest funding round?

    IXICO's latest funding round is PIPE.

  • How much did IXICO raise?

    IXICO raised a total of $6.08M.

  • Who are the investors of IXICO?

    Investors of IXICO include Gresham House Ventures, Innovate UK, The Capital Fund, Touchstone Innovations, YFM Equity Partners and 3 more.

  • Who are IXICO's competitors?

    Competitors of IXICO include AINOSTICS.

  • What products does IXICO offer?

    IXICO's products include CLINICAL PROGRAMME DESIGN & CONSULTATION and 4 more.

  • Who are IXICO's customers?

    Customers of IXICO include Large pharma, BioTech and CRO.

Compare IXICO to Competitors


BioMind is an artificial intelligence company specializing in deep learning for medical imaging. The company has commercialized its AI-assisted diagnostic applications for neurological disorders and is fast expanding to other parts of the body. Logo is a company that develops and markets imaging solutions. The company's product, NeuroQuant, is a medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practices. As a medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant brings accurate and fully automated MRI post-processing capabilities to a physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, multiple sclerosis, epilepsy, and traumatic brain injury. The company also develops OnQ Prostate, a post-processing software that supports the improved detection of clinically significant prostate cancer. Leveraging an advanced diffusion MRI technique called Restriction Spectrum Imaging and powered by AI, the software enables faster, more accurate PI-RADS scoring. was founded in 2001 and is based in San Diego, California.

Oxford Brain Diagnostics Logo
Oxford Brain Diagnostics

Oxford Brain Diagnostics (OBD) has developed a patented approach to treat dementia, called Cortical Disarray Measurement (CDM), as the result of an 8-year collaboration between Dr. Steven Chance (Neuroscience and Pathology) and Prof. Mark Jenkinson (Neuroimaging) at the University of Oxford. Its technology can identify and then measure the progression of the disease and how it responds to treatment by examining changes in the microscopic brain structure extracted from MRI scan data.

Darmiyan Logo

Darmiyan develops fully automated proprietary software that inputs human brain MRIs and produces maps that detect Alzheimer's disease up to fifteen years before symptoms. Its mission is to create a fast, non-invasive, inexpensive, precise, and globally accessible tool for brain health screening and monitoring. Darmiyan's technology provides a platform for presymptomatic diagnosis of neurodegenerative disorders, with precise quantification and localization of microscopic abnormality in the brain.

Icometrix Logo

Icometrix allows users to obtain clinically meaningful data from brain MRI and CT scans for patients with Multiple Sclerosis, Traumatic Brain Injury, Epilepsy, Alzheimer’s Disease, Stroke, etc. The fully automated icobrain software is FDA approved and has market approval in Europe, Japan, Canada, US, India, Brazil, and Australia.


AINOSTICS is a medical data analytics company providing data management and advanced analytics to both healthcare clients and the pharmaceutical industry, with a focus on the early diagnosis and management of neurodegenerative diseases. It was founded in 2018 and is based in Manchester, England.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.